-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Jiangsu Aosaikang Pharmaceutical has entered the administrative examination and approval stage with the imitation of Paricalcitol injection in Category 6 and is expected to be approved in the near future.
Data show that paricalcitol is the latest generation of selective vitamin D receptor agonists, which can effectively reduce parathyroid hormone (PTH) in combination with vitamin D receptors, and is used to treat chronic renal failure patients undergoing hemodialysis.
Sales of Paricalcitol Injections in Public Medical Institutions in China in Recent Years
Source: Terminal competition landscape of China's public medical institutions
Paricalcitol injection was developed by AbbVie and was approved for marketing by the FDA in 1998.
Source: MED2.
In recent years, with the efforts of domestic pharmaceutical companies, AbbVie's paricalcitol injection market share has declined rapidly, from its monopoly in 2017 to less than 20% in the first half of 2020.
Source: Mi Nei Net database
